Nøkkelinformasjon info chevron_right

Viktig informasjon i saken hentes i sanntid direkte fra EPO sitt register (European Patent Register), slik at du enkelt og raskt får oversikt i saken.
Beskrivelse Verdi
Saken / databasen er sist oppdatert info  
Tittel ANTI-C5 ANTIBODIES AND USES THEREOF
Status
Hovedstatus
Detaljstatus 		I kraft info EP patent gjort gjeldende i Norge EP patent besluttet gjeldende i Norge
Patentnummer NO/EP3468990
Europeisk (EP) publiserings nummer EP3468990
EP levert
EP søknadsnummer 17731785.6
EP meddelt
Prioritet 2016.06.14, US 201662349705 P, .... se mer/flere nedenfor
Sakstype Europeisk
Løpedag
Utløpsdato
Allment tilgjengelig
Validert i Norge
Innehaver Regeneron Pharmaceuticals, Inc. (US)
Oppfinner HU, Ying (US) .... se mer/flere nedenfor
Fullmektig ZACCO NORWAY AS (NO)
Lenke til European patent Register Informasjon i saken, dokumenter og patentfamilie
Patentfamilie Se i Espacenet

Sammendrag og figur info chevron_right

EPO translation logo


Se forsidefigur og sammendrag i Espacenet

Beskrivelse og krav info chevron_right

T3

Beskrivelse

Krav

Claims1. An antibody or antigen-binding fragment thereof that binds specifically to complement factor 5 (C5) protein, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (HCVR) comprising the amino acid sequence set forth in SEQ ID NO: 98, and a light chain variable region (LCVR) comprising the amino acid sequence set forth in SEQ ID NO: 106.2. The antibody or antigen-binding fragment thereof of claim 1, comprising a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 353 and/or the light chain comprises the amino acid sequence set forth in SEQ ID NO: 354.3. The antibody or antigen-binding fragment thereof of claim 1 or claim 2, comprising a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 353, and the light chain comprises the amino acid sequence set forth in SEQ ID NO: 354.4. The antibody or antigen-binding fragment thereof of any one of claims 1-3, which is a full antibody molecule.5. A pharmaceutical composition comprising an antibody or antigen-binding fragment thereof of any one of claims 1-4 and a pharmaceutically acceptable carrier or diluent.6. A reusable pen delivery device comprising the pharmaceutical composition of claim 5. 7. An autoinjector delivery device comprising the pharmaceutical composition of claim 5.8. An isolated polynucleotide molecule comprising a nucleotide sequence that encodes a HCVR of an antibody or antigen-binding fragment thereof as set forth in any one of claims 1-4 and a nucleotide sequence that encodes a LCVR of an antibody or antigen-binding fragment thereof as set forth in any one of claims 1-4.9. A recombinant expression vector comprising the polynucleotide molecule of claim 8.10. A cell comprising the recombinant expression vector of claim 9.11. The antibody or antigen-binding fragment thereof of any one of claims 1-4 for use in a method of preventing, treating or ameliorating at least one symptom or indication of a disease or disorder selected from the group consisting of atypical hemolytic uremic syndrome (aHUS), paroxysmal nocturnal hemoglobinuria (PNH), age-related macular degeneration, geographic atrophy, uveitis, neuromyelitis optica, multiple sclerosis, stroke, Guillain Barre Syndrome, traumatic brain injury, Parkinson's disease, a disorder of inappropriate or undesirable complement activation, a hemodialysis complication, hyperacute allograft rejection, xenograft rejection, interleukin-2 induced toxicity during IL-2 therapy, an inflammatory disorder, inflammation of an autoimmune disease, Crohn's disease, adult respiratory distress syndrome, thermal injury, a burn, frostbite, a post-ischemic reperfusion condition, myocardial infarction, capillary leak syndrome, obesity, diabetes, Alzheimer's disease, schizophrenia, epilepsy, atherosclerosis, vasculitis, bullous pemphigoid, C3 glomerulopathy, membraneproliferative glomerulonephritis, diabetic nephropathy, Alport's syndrome, progressive kidney failure, a proteinuric kidney disease, renal ischemia-reperfusion injury, lupus nephritis, balloon angioplasty, post-pump syndrome in cardiopulmonary bypass or renal bypass, renal ischemia, mesenteric artery reperfusion after aortic reconstruction, infectious disease, sepsis, an immune complex disorder, an autoimmune disease, a renal disorder, rheumatoid arthritis, systemic lupus erythematosus (SLE), SLE nephritis, proliferative nephritis, hemolytic anemia, asthma, chronic obstructive pulmonary disease (COPD), emphysema, pulmonary embolism, pulmonary infarct, pneumonia, and myasthenia gravis.12. The antibody or antigen-binding fragment thereof for use according to claim 11, wherein:(a) the method of treatment is prophylactic;(b) the method comprises administering the antibody or antigen-binding fragment thereof in combination with a second therapeutic agent; optionally wherein the second therapeutic agent is selected from the group consisting of an anti-coagulant, an antiinflammatory drug, an antihypertensive, an immunosuppressive agent, a lipid-lowering agent, an anti-CD20 agent such as rituximab, an anti-TNF agent such as infliximab, an anti-seizure agent, a C3 inhibitor, a second anti-C5 antibody, and an anti-thrombotic agent; or (c) the method comprises administering the antibody or antigen-binding fragment thereof subcutaneously, intravenously, intradermally, intraperitoneally, orally, intramuscularly or intracranially.
Hva betyr A1, B, B1, C osv? info

Klasser info chevron_right

Innehaver(e) info chevron_right

Innehaver i EP:
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road Tarrytown, NY 10591 US

Oppfinner(e) info chevron_right

HU, Ying
777 Old Saw Mill River Road Tarrytown, NY 10591 US
LATUSZEK, Adrianna
777 Old Saw Mill River Road Tarrytown, NY 10591 US
ROMANO, Carmelo
777 Old Saw Mill River Road Tarrytown, NY 10591 US
OLSON, William
777 Old Saw Mill River Road Tarrytown, NY 10591 US

Fullmektig info chevron_right

Fullmektig i Norge:
ZACCO NORWAY AS
Postboks 488 0213 OSLO NO ( OSLO kommune, Oslo fylke )

Org.nummer: 982702887
Din referanse: V477683NO00
  • Foretaksnavn:
  • Foretaksform:
  • Næring:
  • Forretningsadresse:
     

Kilde: Brønnøysundregistrene
Fullmektig i EP:
J A Kemp LLP
80 Turnmill Street London EC1M 5QU GB

Prioritet info chevron_right

2016.06.14, US 201662349705 P

2016.10.07, US 201662405561 P

2016.11.15, US 201662422107 P

Anførte dokumenter info chevron_right

EDWIN K.S. WONG ET AL: "Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome", TRANSLATIONAL RESEARCH, vol. 165, no. 2, 1 February 2015 (2015-02-01), pages 306-320, XP055358380, NL ISSN: 1931-5244, DOI: 10.1016/j.trsl.2014.10.010 (B1)

WO-A1-2014/047500 (B1)

Vered Kunik ET AL: "Structural Consensus among Antibodies Defines the Antigen Binding Site", PLoS Computational Biology, vol. 8, no. 2, 23 February 2012 (2012-02-23), page e1002388, XP055123186, DOI: 10.1371/journal.pcbi.1002388 (B1)

EP-B1- 2 328 616 (B1)

Sakshistorikk info chevron_right

Statushistorie

Liste over statusendringer i sakshistorikk
Hovedstatus Beslutningsdato, detaljstatus
EP patent gjort gjeldende i Norge EP patent besluttet gjeldende i Norge
EP under behandling Forespørsel om å gjøre EP patent gyldig er mottatt

Korrespondanse

expand_more file_download  
Liste over sakshistorikk og korrespondanse
Dato Type korrespondanse Journal beskrivelse
Innkommende EP Publiseringsdokument fra EPO
04-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Utgående EP Registreringsbrev (3210) (PTEP3468990)
03-01 Brev UT EP Registreringsbrev (3210) (PTEP3468990)
Innkommende Søknadsskjema Patent
01-01 Søknadsskjema Patent Søknadsskjema Patent
01-02 Fullmakt Regeneron Pharmaceuticals, Inc.
01-03 EP Krav V477683NO00_Claims_NO
Innkommende EP Publiseringsdokument fra EPO
02-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Informasjon om ikke tilgjengelige dokumenter

Betaling info chevron_right

Til betaling:

Beskrivelse Forfallsdato Beløp Status
Årsavgift expand_less Ikke betalt
Årsavgift 9. avg. år (EP) 3710,0 Totalbeløp 3710,0   Gå til betaling

Betalingshistorikk:

Liste av betalinger
Beskrivelse / Fakturanummer Betalingsdato Beløp Betaler Status
32408278 expand_more 2024.06.27 7150 ZACCO NORWAY AS Betalt
Årsavgift 8. avg. år (EP) 2024.06.20 3320 ANAQUA SERVICES Betalt og godkjent
Denne oversikten kan mangle informasjon, spesielt for eldre saker, om tilbakebetaling, internasjonale varemerker og internasjonale design.

Publikasjon(er) info chevron_right

Lenker til publikasjoner og Norsk Patenttidende (søkbare tekstdokumenter)

Oversettelse av europeisk patentskrift
Allment tilgjengelig patentsøknad
Norsk Patenttidende - ved meddelelse
Nye digitale Norske Tidende, nyhet om tjenesten ved lansering
Om Norske Tidende
Hva betyr A1, B, B1, C osv? info
Kapitler uten data er fjernet. Melding opprettet: 26.04.2025 04:46:53